CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows from Operating Activities:
Net income	$ 130,911	$ 67,193
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	14,276	11,672
Non-cash compensation	13,463	12,634
Amortization and impairment of operating lease right of use assets	19,702	18,558
Loss (gain) on disposal of property and equipment	8	(94)
(Gain) loss on equity method investments	(31,092)	2,980
Write-off of other comprehensive income	0	(15)
Deferred income taxes	22,716	(4,036)
Equity in earnings from equity method investments	(2,488)	(964)
Amortization of deferred debt issuance costs/debt discount	432	437
Return on equity method investments	2,683	2,744
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(22,787)	8,997
Other current assets	3,560	(3,469)
Other assets	(52)	(675)
Accounts payable	(6,530)	(6,452)
Accrued expenses	(1,627)	27,990
Other long-term obligations	(1,736)	20,746
Operating lease liabilities	(17,955)	(16,365)
Operating lease right of use assets	(1,524)	(1,924)
Net cash provided by operating activities	121,960	139,957
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets	25	21
Proceeds from sale of property and equipment	42	80
Purchases of property and equipment	(2,943)	(1,701)
Investments in equity method investees	0	(875)
Proceeds from sale of equity method investment	0	17,876
Acquisitions of businesses, net of cash acquired	(2,503)	(299,723)
Net cash used in investing activities	(5,379)	(284,322)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	623	2,947
Proceeds from issuance of stock to employee stock purchase plan	1,961	1,686
Shares withheld to pay taxes on non-cash compensation	(6,944)	(6,384)
Noncontrolling interest distribution	(794)	(372)
Proceeds from borrowings under revolving line of credit	389,200	424,500
Repayments of borrowings under revolving line of credit	(410,200)	(259,500)
Principal payments of long-term obligations	(5,392)	(4,675)
Purchase of company stock	(74,074)	0
Provider relief fund advance	(1,672)	70,000
Net cash (used in) provided by financing activities	(107,292)	228,202
Net increase in cash, cash equivalents and restricted cash	9,289	83,837
Cash, cash equivalents and restricted cash at beginning of period	83,357	96,490
Cash, cash equivalents and restricted cash at end of period	92,646	180,327
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	1,914	3,292
Cash paid for income taxes, net of refunds received	8,667	8,153
Cash paid for operating lease liabilities	19,479	18,289
Cash paid for finance lease liabilities	1,017	986
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	20,689	18,891
Right of use assets obtained in exchange for finance lease liabilities	527	487
Reductions to right of use assets resulting from reductions to operating lease liabilities	$ 904	$ 407